Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2020-11-10 Investor Presentation
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Further to our intimation dated November 09, 2020 regarding approval of un-audited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and half year ....
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation for Quarter 2 – Financial Year 2020-2021' and contains detailed financial data including standalone and consolidated income statements, balance sheets, operational highlights, and financial performance metrics for Q2 and H1 FY21. It includes operational income, EBITDA, PAT, EPS, and segment information, which are typical contents of an earnings presentation. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The presence of detailed financial tables and operational commentary confirms it is a presentation of quarterly earnings results rather than just an earnings release summary or a regulatory filing. Therefore, the document fits the category of an Investor Presentation (IP) focused on quarterly financial results and company overview.
2020-11-10 English
We write to inform you that the Board of Directors of the Company at its meeting held on November 09, 2020 has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2020-11-09 English
We write to inform you that the Board of Directors of the Company at its meeting held on November 09, 2020 has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2020-11-09 English
Intimation of Schedule of Analysts / Institutional Investors meeting over conference call under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. Pursuant ....
Regulatory Filings Classification · 95% confidence The document is an intimation letter to the stock exchange about a scheduled conference call with analysts and institutional investors to discuss the financial performance for the quarter ended September 30, 2020. It includes details about the date, time, and dial-in numbers for the earnings call. There is no actual financial data or detailed financial report included, only an announcement of the upcoming earnings call. According to the classification rules, such a document is best classified as a Call Transcript (CT) category if it contained the full transcript, but since this is only an invitation/intimation for the call, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement under SEBI regulations about the call schedule, not the call transcript itself or the earnings release. The document length is short and it does not contain financial results or detailed analysis, so it is not an Earnings Release (ER) or Interim Report (IR).
2020-11-05 English
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide ....
Regulatory Filings
2020-11-04 English
Notice of Board Meeting to be held on Monday, November 09, 2020. In continuation with our earlier notice for the closure of trading window and in accordance with the provisions of Regulation ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve unaudited financial results for the quarter and half year ended September 30, 2020. It also includes information about the closure of the trading window in compliance with SEBI regulations. The document is short (2630 characters) and serves as an announcement of the upcoming board meeting and trading window closure, not the financial results themselves or detailed financial data. Therefore, it is an announcement related to management and board activities but does not report changes in board members or senior management. It is not a full financial report or earnings release. The best fitting category is Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories.
2020-11-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.